Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, Europe, Latin America, the Asia Pacific, and Africa. The company operates in Pharmaceuticals and Consumer Products segments. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; and products in the therapeutic areas of pain management, neurology, dermatology, liver diseases, and other areas. The company also provides consumer wellness products, such as Complan; EverYuth, a range of skincare products; Nycil; Glucon-D glucose powder; Nutralite; Nutralite Doodhshakti, a portfolio of dairy products; and various other products. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, ophthalmology, inflammation, rheumatology, hepatology, infectious disease, etc. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is based in Ahmedabad, India.

Zydus Lifesciences Limited

Zydus Lifesciences Ltd. is a global lifesciences company focused on delivering care and support for patients, backed by innovation and science.

	Dec '13	Mar '14	Jun '14	Sep '14	Dec '14	Mar '15	Jun '15	Sep '15	Dec '15	Mar '16	Jun '16	Sep '16	Dec '16	Mar '17	Jun '17	Sep '17	Dec '17	Mar '18	Jun '18	Sep '18	Dec '18	Mar '19	Jun '19	Sep '19	Dec '19	Mar '20	Jun '20	Sep '20	Dec '20	Mar '21	Jun '21	Sep '21	Dec '21	Mar '22	Jun '22	Sep '22	Dec '22	Mar '23	Jun '23	Sep '23	Dec '23	Mar '24
net income	1.86B -	2.39B 28.62%	2.40B 0.42%	2.78B 15.77%	2.82B 1.37%	3.50B 24.29%	3.53B 0.86%	3.91B 10.62%	3.90B 0.34%	8B 105.34%	3.56B 55.47%	3.38B 5.22%	2.82B 16.59%	5.12B 81.92%	1.38B 72.98%	5.03B 263.66%	5.43B 7.95%	5.91B 8.74%	4.61B 22.05%	4.17B 9.34%	5.11B 22.32%	4.60B 9.91%	3.04B 34.01%	1.07B 64.69%	3.74B 248.79%	3.92B 4.81%	4.54B 15.85%	4.73B 4.27%	5.27B 11.36%	6.79B 28.79%	5.87B 13.52%	30.02B 411.29%	5.00B 83.33%	3.97B 20.58%	5.18B 30.42%	5.22B 0.81%	6.23B 19.22%	2.97B 52.38%	10.87B 266.45%	8.01B 26.33%	7.68B 4.11%	11.82B 53.99%
depreciation and amortization																																				1.82B -	1.82B 0.11%	1.79B 1.65%	1.80B 0.67%	1.84B 2.45%	1.95B 5.75%
deferred income tax
stock based compensation
change in working capital
accounts receivables
inventory
accounts payables
other working capital
other non cash items	-1.86B -	-2.39B 28.62%	-2.40B 0.42%	-2.78B 15.77%	-2.82B 1.37%	-3.50B 24.29%	-3.53B 0.86%	-3.91B 10.62%	-3.90B 0.34%	-8B 105.34%	-3.56B 55.47%	-3.38B 5.22%	-2.82B 16.59%	-5.12B 81.92%	-1.38B 72.98%	-5.03B 263.66%	-5.43B 7.95%	-5.91B 8.74%	-4.61B 22.05%	-4.17B 9.34%	-5.11B 22.32%	-4.60B 9.91%	-3.04B 34.01%	-1.07B 64.69%	-3.74B 248.79%	-3.92B 4.81%	-4.54B 15.85%	-4.73B 4.27%	-5.27B 11.36%	-6.79B 28.79%	-5.87B 13.52%	-30.02B 411.29%	-5.00B 83.33%	-3.97B 20.58%	-5.18B 30.42%	-3.41B 34.27%	-4.41B 29.53%	-1.18B 73.26%	-9.07B 668.73%	-6.17B 32.04%	-5.73B 7.06%	-11.82B 106.34%
net cash provided by operating activities																																				3.64B -	3.63B 0.11%	3.57B 1.65%	3.60B 0.67%	3.68B 2.45%	3.90B 5.75%
investments in property plant and equipment
acquisitions net
purchases of investments
sales maturities of investments
other investing activites
net cash used for investing activites
debt repayment
common stock issued
common stock repurchased
dividends paid
other financing activites
net cash used provided by financing activities
effect of forex changes on cash
net change in cash																																				3.64B -	3.63B 0.11%	3.57B 1.65%	3.60B 0.67%	3.68B 2.45%	3.90B 5.75%
cash at beginning of period																																				4.20B -	7.84B 86.55%	1.35B 82.72%	4.93B 263.81%	5.39B 9.36%	9.07B 68.39%
cash at end of period																																				7.84B -	11.47B 46.34%	4.93B 57.05%	8.52B 73.00%	9.07B 6.44%	12.97B 42.95%
operating cash flow																																				3.64B -	3.63B 0.11%	3.57B 1.65%	3.60B 0.67%	3.68B 2.45%	3.90B 5.75%
capital expenditure
free cash flow																																				3.64B -	3.63B 0.11%	3.57B 1.65%	3.60B 0.67%	3.68B 2.45%	3.90B 5.75%

COM:ZYDUSLIFE

Zydus Lifesciences Ltd.

Last Close

944.05

22/11 10:00

Market Cap

1.17T

Beta: -

Volume Today

295.38K

Avg: -

Preview